On the contrary, after antagonizing ERβ, the nuclear translocation of STAT3 increased, indicating that STAT3 could be a downstream signalling molecule of ERβ, and that D1 could exhibit its anti-NSCLC function through the ERβ-STAT3 pathway. The gene discussed is ESR2; the disease is non-small cell lung carcinoma.